MedTrace Logo

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2021-04-28

No results posted yet for this study

Summary

This trial is a single-center two arm, open label observational prospective study, that will evaluate the safety and efficacy of crisaborole ointment, 2% alone compared to a combination therapy of crisaborole and a topical corticosteroid (Triamcinolone Acetonide Ointment, 0.1%) over a 8 week period for the treatment of mild to moderate atopic dermatitis.

Conditions

Interventions

DRUG

Crisaborole 2% Topical Application Ointment [EUCRISA]

Ointment

DRUG

Triamcinolone Acetonide 0.1% Ointment

Topical Corticosteroid

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Clinical Research Center of the Carolinas

    lead OTHER

Principal Investigators

  • Todd Schlesinger, MD · Clinical Research Center of the Carolinas

Eligibility

Min Age
2 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2020-07-14
Completion
2020-09-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008784 on ClinicalTrials.gov